PT-141 Guide
Bremelanotide Dosage, Mechanism & Science
Complete PT-141 (bremelanotide) guide covering mechanism, dosage, FDA approval as Vyleesi, side effects, and how it differs from Viagra.
What Is PT-141?
PT-141, chemically known as bremelanotide, is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It was originally derived from Melanotan II — a compound investigated for tanning — when researchers noticed its potent effects on sexual arousal as an unintended finding. PT-141 retained the sexual arousal activity while the tanning properties were largely removed in its structural design.
The FDA approved bremelanotide in 2019 as Vyleesi (1.75mg subcutaneous auto-injector) for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first and only non-hormonal drug approved specifically for female sexual dysfunction acting through the central nervous system. Unlike estrogen-based treatments that address lubrication or vaginal atrophy, Vyleesi addresses the neurological origin of low desire.
In the research community, PT-141 is used at doses lower than the FDA-approved 1.75mg (typically 0.5–1mg) primarily to reduce the most common side effect: nausea. Both the research form (lyophilized powder for reconstitution) and the branded Vyleesi auto-injector contain the same active molecule.
Vyleesi (bremelanotide 1.75mg) — first non-hormonal CNS drug approved for HSDD in premenopausal women.
Acts on melanocortin receptors 3 and 4 in the hypothalamus — the brain regions governing sexual motivation and dopamine release.
Inject 45–90 minutes before activity. Half-life of 2–3 hours. On-demand use — not daily dosing.
How PT-141 Works: CNS vs. Blood Flow
Melanocortin Receptor Activation
PT-141 activates MC3R and MC4R receptors concentrated in the hypothalamus — particularly in the medial preoptic area (MPOA), the brain's primary sexual motivation center. This activation triggers
PT-141 vs. PDE5 Inhibitors (Viagra/Cialis)
Sildenafil (Viagra) and tadalafil (Cialis) inhibit PDE5 enzyme in penile smooth muscle, preventing cGMP breakdown and maintaining vasodilation — increasing blood flow to erectile tissue. They require
Women: HSDD Mechanism
In women with HSDD, the problem is neurological — reduced central dopaminergic tone in sexual motivation pathways, often compounded by increased serotonergic inhibition. PT-141's MC4R activation
Men: Off-Label Sexual Function
PT-141 is not FDA-approved for male sexual dysfunction but is extensively studied and used in research settings. Published studies demonstrate significant improvements in erectile function scores, inc
PT-141 Dosage & Protocol
FDA-Approved Dose (Vyleesi)
Dose: 1.75mg subcutaneous. Timing: 45 minutes before activity. Auto-injector: pre-filled pen. Max frequency: once per 24 hours. Not for daily use — on-demand only. Indication: HSDD in premenopausal wo
Research Community Protocol
Dose: 0.5–1mg subcutaneous. Timing: 60–90 minutes before activity. Lower dose reduces nausea significantly. Reconstituted from lyophilized powder. Men typically use 1mg starting dose. Women often find
Side Effects & Safety
Common Side Effects
Nausea (most common): Dose-dependent — occurs in approximately 40% of users at 1.75mg, significantly less at 0.5–1mg. Usually mild to moderate, resolves within 1–2 hours. Taking with a light meal or g
Safety & Contraindications
Do NOT combine with alkyl nitrates: Same contraindication as PDE5 inhibitors — combined vasodilatory effect can cause severe hypotension. This includes poppers (amyl/butyl nitrate) used recreationally
PT-141 in Context: Comparisons
PT-141 vs. Kisspeptin
Kisspeptin is a neuropeptide that activates the HPG (hypothalamic-pituitary-gonadal) axis, primarily studied for fertility and reproductive hormone regulation. It has secondary effects on sexual behav
PT-141 vs. Flibanserin (Addyi)
Flibanserin (Addyi) is a daily oral pill for HSDD acting on serotonin and dopamine receptors. It has modest efficacy and severe interactions with alcohol (dangerous hypotension). PT-141 is used on-dem
Guide FAQs
Complete PT-141 (bremelanotide) guide covering mechanism, dosage, FDA approval as Vyleesi, side effects, and how it differs from Viagra.
Yes. Shotlee supports tracking PT-141 doses, side effects, and health metrics. It is free to use.
PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Pt 141 research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.
Before starting Pt 141, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.
Evidence-based lifestyle modifications that complement Pt 141 protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Pt 141 data in Shotlee to identify which combinations drive your best results.
References
- [1]Clinical TrialKingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- [2]Clinical TrialClayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337.
- [3]Clinical TrialDiamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638.
- [4]FDAVyleesi (bremelanotide injection). FDA Prescribing Information. AMAG Pharmaceuticals, Inc. 2019.
Track Your PT-141 Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free